Carnegie Mellon and Yale Study in Mice Shows Promise for Treating Genetic Conditions During Early Stages of Development
Researchers at Carnegie Mellon University and Yale University have for the first time used a gene editing technique to successfully cure a genetic condition in utero in a mouse model. Their findings, published in Nature Communications, present a promising new avenue for research into treating genetic conditions during fetal development.
An estimated 8 million children are born each year with severe genetic disorders or birth defects. Genetic conditions can often be detected during pregnancy using amniocentesis, but there are no treatment options to correct these genetic conditions before birth.
“Early in embryonic development, there are a lot of stem cells dividing at a rapid pace. If we can go in and correct a genetic mutation early on, we could dramatically reduce the impact the mutation has on fetal development or even cure the condition,” said Danith Ly, professor of chemistry in Carnegie Mellon’s Mellon College of Science.
In this study, the researchers used a peptide nucleic acid-based gene editing technique that they had previously used to cure beta thalassemia, a genetic blood disorder that results in the reduced production of hemoglobin, in adult mice.
Peptide nucleic acids are synthetic molecules that combine a synthetic protein backbone with the nucleobases found in DNA and RNA. The PNAs used in this study were created by Ly at Carnegie Mellon’s Center for Nucleic Acids Science and Technology (CNAST), a leading center for PNA science.
Their technique uses an FDA-approved nanoparticle to deliver PNA molecules paired with donor DNA to the site of a genetic mutation. When the PNA-DNA complex identifies a designated mutation, the PNA molecule binds to the DNA and unzips its two strands. The donor DNA binds with the faulty DNA and spurs the cell’s DNA repair pathways into action, allowing it to correct the error.
In the current study, the researchers used a technique similar to amniocentesis to inject the PNA complex into the amniotic fluid of pregnant mice whose fetuses carried a mutation in the beta-globin gene that causes beta thalassemia.
With just one injection of the PNA during gestation, the researchers were able to correct 6 percent of the mutations. This 6 percent correction was enough to cause dramatic improvements in the mice’s symptoms of beta thalassemia – and enough for the mice to be considered cured. Mice that were treated using PNA while in utero had levels of hemoglobin that were within the normal range, less spleen enlargement and increased survival rates.
The researchers also noted that there were no off-target effects from the treatment, a finding that might suggest this method would be preferable over other gene editing techniques like CRISPR/Cas9, which can erroneously damage off-target DNA.
“CRISPR is much easier to use, which makes it ideal for laboratory research. But the off-site errors make it less useful for therapeutics,” said Ly. “The PNA technique is more ideal for therapeutics. It doesn’t cut the DNA, it just binds to it and repairs things that seem unusual. We looked at 50 million samples and couldn’t find one offsite error when we used our PNA gene editing technique.”
The researchers believe that their technique might be able to achieve even higher success rates if they can administer it multiple times during gestation. They also hope to see if their technique can be applied to other conditions .
Receive an email update when we add a new GENE EDITING article.
The Latest on: Curing a genetic condition in utero
via Google News
The Latest on: Curing a genetic condition in utero
- Female Scientists Accept Nobel Prizes in Physics and Chemistry on December 11, 2018 at 2:21 pm
“With evolution in our hands, with the ability to set genetic diversity and tailor the forces of ... to fix the carbon in our atmosphere, to cure disease, to make us younger, more beautiful, or we can ... […]
- Prenatal gene editing success lays path for treating congenital diseases in the womb on October 8, 2018 at 5:35 pm
In this particular experiment the fetus was not treated while it was in the womb. In order to ensure accurate ... breakthrough is a major step forward in finding a cure for a large number of genetic d... […]
- In Utero Gene Editing Technique Developed At CMU And Yale Could Be Used In Humans on August 2, 2018 at 2:19 pm
A study by Carnegie Mellon University and Yale University has found a gene editing technique administered in fetal mice can cure a genetic blood disease before birth. This is the first time this techn... […]
- Gene editing can treat thalassaemia in womb on July 11, 2018 at 7:00 pm
Mice treated using PNA while in utero showed levels ... If we can correct a genetic mutation early , we could dramatically reduce the impact the mutation has on foetal development or even cure the con... […]
- Gene editing technique can treat thalassemia in womb on July 11, 2018 at 1:35 am
Mice treated using PNA while in utero showed levels ... If we can go in and correct a genetic mutation early on, we could dramatically reduce the impact the mutation has on foetal development or even ... […]
- Gene Editing Technique Cures Genetic Disorder in Utero on July 10, 2018 at 7:52 am
Researchers have used a gene editing technique to successfully cure a genetic condition in a mouse model ... Mice that were treated using PNA while in utero had levels of hemoglobin that were within t... […]
- Gene-editing technique cures genetic disorder in utero on July 9, 2018 at 8:55 am
Researchers at Carnegie Mellon University and Yale University have for the first time used a gene editing technique to successfully cure a genetic condition in a mouse model ... Mice that were treated ... […]
- Fusing a lifeline in the womb on June 20, 2018 at 4:24 am
Elianna, born on February 1 with a robust cry and a cap of gleaming black hair, has a genetic disease that ... transfusions in the womb kept her alive, but only treated her illness. The bone-marrow tr... […]
- In first, doctors treat rare genetic disorder with an injection in utero on April 27, 2018 at 9:12 am
The in utero injections treated a rare, recessive genetic condition called X-linked hypohidrotic ectodermal ... The EDA gene is highly conserved in vertebrates, so it’s easy to replicate (and cure) th... […]
via Bing News